Charming Medical Faces Class Action Over Fraud Allegations Amid Stock Surge to $29.36
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Lawsuit Initiation: Bragar Eagel & Squire has filed a class action lawsuit against Charming Medical in the Southern District of New York on behalf of investors who purchased shares between October 10 and November 12, 2025, with a deadline of February 17, 2026, to apply as lead plaintiff.
- Fraud Allegations: The complaint alleges that Charming failed to disclose its stock was manipulated through fraudulent social media promotions, causing its price to surge from $4.00 to $29.36, which raises serious concerns about the company's transparency and investor trust.
- Trading Suspension: On November 12, 2025, the SEC halted trading of Charming's stock due to the company's failure to provide necessary information, indicating significant compliance issues that could hinder future capital raising efforts.
- Investor Rights Protection: The law firm encourages affected investors to reach out to understand their legal rights, highlighting the importance of investor protection mechanisms in the securities market and their strategic significance in maintaining market confidence.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
